Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00148642 · ClinicalTrials.gov registry record · Phase 3

Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

A Phase 3 study, sponsored by C. R. Bard.

Completed
Registry status
Phase 3
Development phase
2,003
Enrollment target

NCT00148642 is a Phase 3 study that has completed, run by C. R. Bard. The registered enrollment target is 2,003 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00148642, a Phase 3 study, has completed, sponsored by C. R. Bard.

COMPLETED
Registry status
Phase 3
Development phase
2,003 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the use of a silver-coated endotracheal tube (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non silver-coated ETT in patients who have been mechanically ventilated for \>= 24 hours.

Interventions

  • DEVICE silver salts coated endotracheal tube
  • DEVICE uncoated endotracheal tube

Trial Details

FieldValue
Enrollment Target 2,003 participants
Start Date 2002-11
Est. Completion 2006-03
Phase Phase 3

Sponsor

C. R. Bard

75 total trials

What the Registry Record Tells You About NCT00148642

The ClinicalTrials.gov registry entry for NCT00148642 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,003 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which silver salts coated endotracheal tube is the first listed.

NCT00148642 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00148642 about?

NCT00148642 is a clinical study titled "Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)". The purpose of this study is to determine if the use of a silver-coated endotracheal tube (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non silver-coated ETT in patients who have been mechanically ventilated for \>= 24 hours.

What is the current status of trial NCT00148642?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,003 participants. The study started on 2002-11. Estimated completion is 2006-03.

What interventions are being tested in trial NCT00148642?

The interventions under investigation include: silver salts coated endotracheal tube (DEVICE), uncoated endotracheal tube (DEVICE).

Who is sponsoring clinical trial NCT00148642?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.